Webcast MRI on cancer and Neuroscience

Nano-responsive and theranostic contrast agents

 · Europe/Berlin

About This Webcast

The advent of responsive contrast agents and nanoparticle drug delivery systems (nano-DDSs) is opening new pathways to understanding pathophysiology using MRI. Nanoparticles have for many years been investigated as possible MRI contrast agents. Nano-carriers for DDSs can contain multiple functional elements, such as therapeutic drugs, MRI contrast agents, fluorescent or luminescent dyes, and radioisotopes, without serious changes to the particle kinetics/dynamics. The development of such multifunctional nano-DDSs and imaging has accordingly become a subject of widespread research. I will summarize our research into nano-DDS-based contrast agents for cancer and neuroscience 1,2.

Speakers

Dr. Ichio Aoki

Dr. Ichio Aoki

Institute for Quantum Medical Science (iQMS), National Institutes for Quantum Science and Technology (QST) , Group Leader, Functional and Molecular Imaging Group, Department of Molecular Imaging and Theranostics, iQMS, QST.

Ichio Aoki initially learned NMR science from Dr. Kohji Fukuda (physics/physiology) in 1993-1994, and received a MSc for quantitative brain perfusion MRI, working with Dr. Chuzo Tanaka (neurosurgery, 1996) in Kyoto, Japan. He also received a Ph.D. for research and development of manganese-enhanced MRI (MEMRI) with Dr. Tanaka in 1999 (Kyoto, Japan). A visiting fellow position (2000-2002) in the National Institute of Neurological Disorders and Stroke (NINDS) at NIH (Bethesda, USA) was focused on brain functional and contrast-agent research using high-field MRI with Dr. Alan P Koretsky. In the autumn of 2006, Dr. Aoki moved to the Molecular Imaging Center, National Institute of Radiological Sciences (NIRS; Chiba, Japan) as a leader of the Imaging Physics Team (2007-2011) and the Multimodal Molecular Imaging Team (2011-2015) at NIRS. In 2016, the NIRS was integrated to the National Institutes for Quantum and Radiological Science (QST), Japan. Dr. Aoki is a senior investigator of the Institute for Quantum Medical Science (iQMS) and a group leader of the Functional and Molecular Imaging Group (2016-present) at QST. He has focused on finding something new in preclinical MRI. His interest began with manganese-enhanced MRI and extended to the development of nanoparticle-based functional contrast agents for neuroscience and cancer research. Executive boards: Japanese Society for Magnetic Resonance in Medicine (JSMRM), Japanese Society for Molecular Imaging (JSMI). Committee: Past-chair of Japanese Chapter of ISMRM, ISMRM Annual Meeting Program Committee (2014-2017). Academic Journal editor: Molecular Imaging and Biology (Springer Nature), Plos one (PLOS). Visiting lecturers: Tokyo Institute of Technology, Kyoto University, Kyushu University, Okayama University, Tokyo Medical and Dental University.